A buyer's guide comparing online tirzepatide providers. It's an affiliate-style roundup more than news, so read it with that in mind.
Recap by typeshit. Full story at Forbes.
New generics and steady prices drove the jump in sales value, with Eli Lilly's tirzepatide leading the market.
UBS says volumes grew about 55% while net prices fell roughly 14%, and points to about 500,000 people joining Lilly's Medicare bridge program in a few months.
A new market report values the sector at $97.5 billion in 2025 and expects oral and multi-pathway drugs to grow fastest as Medicare coverage starts in mid-2026.
Forbes compares what brand-name semaglutide and tirzepatide cost against compounded GLP-1 versions.
A short social explainer from ABC7 Chicago on Lilly's experimental retatrutide and how it targets three hormones tied to appetite, with more at the station's link.
BuzzFeed's celebrity desk picks up a widely viewed post joking about a new GLP-1 side effect, following slang like Ozempic face. Details are thin.
Loading…